Effect of time delay on survival in patients with non-small cell lung cancer — A Malaysian study

Loh, Li‐Cher; Chan, Li-Yen; Tan, Ru Yu; Govindaraju, Selvaratnam; Ratnavelu, Kananathan; Kumar, Sumit; Raman, Sree; Vijayasingham, P; Thayaparan, Tarmizi

doi:10.1177/10105395060180011101

Cited by 11 publications

(12 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Eighteen studies examined the association between timeliness and one or more outcomes, including 15 studies that examined survival,6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 4 studies that examined stage distribution11 16 21 22 and 1 that examined tumour growth 23. Eight studies that described an intervention to improve timeliness of care were identified 24 25 26 27 28 29 30 31…”

Section: Resultsmentioning

confidence: 99%

“…Four Canadian studies21 34 35 36 and four Japanese studies12 15 16 37 were identified, including several studies that examined delays in care after mass population-based screening. We also included two studies from Turkey,17 38 one study from Australia24 and one study from Malaysia 9…”

Section: Resultsmentioning

confidence: 99%

“…Fifteen studies looked at the effect of timeliness on survival and reported mixed results, including eight studies that showed no association between timeliness and outcome 6 7 8 9 10 11 12 13…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Timeliness of care in patients with lung cancer: a systematic review

Olsson

Schultz

Gould

2009

Thorax

164

176

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Timeliness of care in patients with lung cancer: a systematic review

Olsson

Schultz

Gould

2009

Thorax

164

176

View full text Add to dashboard Cite

“…The proportion of patients receiving chemotherapy as their first treatment (alone or in combination with radiotherapy) ranged from 25 to 69%. No study demonstrated an association between TTC and survival among the entire meta‐analysis when considering TTC intervals from 30 days to 6 months or by per day analyses . One study did show improved survival with early TTC; however, this was observed only in the subgroup of patients with overall survival ≥5 years .…”

Section: Methodsmentioning

confidence: 98%

“…S5), 514 from MEDLINE, 72 from the Cochrane Library and an additional 12 papers identified from reference lists. Of these, 11 papers were reviewed. Studies varied by publication date (2000–2013) and size ( n = 21–10 583) and reported data for a heterogeneous group of patients (stages I–IV non‐small‐cell lung cancer (NSCLC) and limited‐ and extensive‐stage small‐cell lung cancer (SCLC)) as shown in Tables and .…”

Section: Methodsmentioning

confidence: 99%

Timely initiation of chemotherapy: a systematic literature review of six priority cancers – results and recommendations for clinical practice

Alexander

Blum

Burbury

et al. 2017

Internal Medicine Journal

View full text Add to dashboard Cite

This review evaluated the association between time-to-chemotherapy (TTC) and survival in six priority cancers. A systematic review of the literature was undertaken for papers indexed in the MEDLINE and Cochrane Library databases from the earliest index until April 2014. The methodology used has been published in a separate paper (Guidelines for timely initiation of chemotherapy: a proposed framework for access to medical oncology and haematology cancer clinics and chemotherapy services). The optimal timing of chemotherapy in breast cancer is unclear as available studies are of low quality, report inconsistent results and are limited to the adjuvant setting. However, increased TTC may have a negative prognostic impact, and delays beyond 4 weeks should be avoided. Studies suggest that the optimal timing for initiation of adjuvant chemotherapy for surgically resected colorectal cancer is 4-8 weeks post-surgery. Timing of chemotherapy for metastatic colorectal cancer does not influence survival. There is a paucity of studies to guide the timing of chemotherapy for the treatment of lymphoma and myeloma; no definitive conclusions can be drawn, and clinician discretion should be applied. The optimal timing of chemotherapy in lung cancer is unclear; however, rapid tumour growth and poor disease prognosis suggest that delays should be avoided wherever possible. The optimal timing of chemotherapy in ovarian cancer is unclear as available studies are of low level, report inconsistent results and are limited to the post-surgery setting; however, increased TTC may have a negative prognostic impact; therefore, delays beyond 4 weeks should be avoided.

show abstract

Influence of timeliness and receipt of first treatment on geographic variation in non‐small cell lung cancer mortality

Wah

Stirling

Ahern

et al. 2020

Intl Journal of Cancer

View full text Add to dashboard Cite

Mortality from non‐small cell lung cancer (NSCLC) exhibits substantial geographical disparities. However, there is little evidence on whether this variation could be attributed to patients' clinical characteristics and/or socioeconomic inequalities. This study evaluated the independent and relative contribution of the individual‐ and area‐level risk factors on geographic variation in 2‐year all‐cause mortality among NSCLC patients. In the Hierarchical‐related regression approach, we used the Bayesian spatial multilevel logistic regression model to combine individual‐ and area‐level predictors with outcomes while accounting for geographically structured and unstructured correlation. Individual‐level data included 3330 NSCLC cases reported to the Victoria Lung Cancer Registry between 2011 and 2016. Area‐level data comprised socioeconomic disadvantage, remoteness and pollution data at the postal area level in Victoria, Australia. With the inclusion of significant individual‐ and area‐level risk factors, timely (≤14 days) first definitive treatment (odds ratio [OR] = 0.73, 95% credible interval [Crl] = 0.56‐0.94) and multidisciplinary meetings (MDM) (OR = 0.74, 95% Crl = 0.59‐0.93) showed an independent association with a lower likelihood of NSCLC 2‐year all‐cause mortality. Timely and delayed (>14 days) first nondefinitive treatment, no treatment, advanced clinical stage, smoking, poor performance status, public hospital insurance and area‐level deprivation were independently associated with a higher likelihood of 2‐ and 5‐year all‐cause mortality. NSCLC's 2‐year all‐cause mortality exhibited substantial geographic variation, mainly associated with timeliness and receipt of first definitive treatment, no treatment followed by patient prognostic factors with some contribution from area‐level deprivation, MDM and public hospital insurance. This study highlights NSCLC patients should receive the first definitive treatment within the recommended 14‐days from diagnosis.

show abstract

Effect of time delay on survival in patients with non-small cell lung cancer — A Malaysian study

Cited by 11 publications

References 6 publications

Timeliness of care in patients with lung cancer: a systematic review

Timeliness of care in patients with lung cancer: a systematic review

Timely initiation of chemotherapy: a systematic literature review of six priority cancers – results and recommendations for clinical practice

Influence of timeliness and receipt of first treatment on geographic variation in non‐small cell lung cancer mortality

Contact Info

Product

Resources

About